Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.

about

Zika Fetal Neuropathogenesis: Etiology of a Viral Syndrome Oral Ulcers in Juvenile-Onset Systemic Lupus Erythematosus: A Review of the Literature.Juvenile systemic lupus erythematosus in Turkey: demographic, clinical and laboratory features with disease activity and outcome.

P2860

Q26700454-61D03390-762F-41A5-B60D-2A944C521102 Q39287179-702C9944-740A-469E-A6A0-71CDB8F1DA80 Q46867176-B3CFBCA9-A7DA-448A-95B1-343B658F2DDA

P2860

Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.

Item

http://www.wikidata.org/entity/Q38771936

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.

@en

type

Item

label

Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.

@en

prefLabel

Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.

@en

P1476

Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.

@en

P2093

Angela Midgley

http://www.w3.org/2001/XMLSchema#string

Colin Thorbinson

http://www.w3.org/2001/XMLSchema#string

Eve Smith

http://www.w3.org/2001/XMLSchema#string

Louise Oni

http://www.w3.org/2001/XMLSchema#string

Michael W Beresford

http://www.w3.org/2001/XMLSchema#string

P2860

Unmet medical needs in systemic lupus erythematosus

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

The 1982 revised criteria for the classification of systemic lupus erythematosus

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.

P2888

s40272-016-0170-8

P304

181-195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40272-016-0170-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1020055599

http://www.w3.org/2001/XMLSchema#string

P698

26971103

http://www.w3.org/2001/XMLSchema#string

Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.

about

P2860

P2860

Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698